(Third from left) Dr Arumugam Muruganandam, MD & CSO, Affigenix Biosolutions
It won the award for developing the in-vitro diagnostic kit for diabetes management.
"We are hoping our simple, user friendly, affordable lateral flow kit will become preferred companion diagnostic kit along with the routine Glucose test and HbA1c measurement for diabetes management. The kit will enable doctors to make informed decision and prescribe personalized medicine that will be more efficacious in controlling glucose levels in ~7 million diabetic patients who depend on insulin in India alone," added Dr Arumugam Muruganandam, MD & CSO, Affigenix Biosolutions.
The India Innovation Growth Programme is a joint initiative of the Department of Science and Technology, Government of India; Lockheed Martin Corporation; Indo-US Science and Technology Forum, Federation of Indian Chambers of Commerce and Industry; Stanford Graduate School of Business and the IC2 Institute at the University of Texas.
The aim of this programme is to accelerate innovative Indian technologies into the global markets.
The India Innovation Growth Program is the only program of its kind, focusing on teaching using world-class commercialization strategies and the business development assistance provided.